Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

Equities researchers at Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of Envista in a research report ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

MONTREAL, Feb. 3, 2025 /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in ...

Op maandag handhaafde Leerink Partners een Outperform-rating voor Arvinas Inc. (NASDAQ:ARVN), maar verlaagde het koersdoel van €62,00 naar €49,00. De aanpassing volgt op de verwachting van de VERITAC- ...

Op vrijdag heeft Leerink Partners het koersdoel voor Sanofi (SAN:FP) (NASDAQ: SNY) verhoogd van €113,00 naar €120,00, terwijl het bedrijf zijn Outperform-rating voor de aandelen handhaafde. Sanofi, mo ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

The Leerink Partners Global Healthcare Conference is a premier gathering of industry leaders, investors and innovators, providing a platform to explore the latest advancements and trends shaping ...